The Ureter Cancer drugs in development market research report provides comprehensive information on the therapeutics under development for Ureter Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Ureter Cancer. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Ureter Cancer and features dormant and discontinued products.

GlobalData tracks 46 drugs in development for Ureter Cancer by 40 companies/universities/institutes. The top development phase for Ureter Cancer is phase ii with 25 drugs in that stage. The Ureter Cancer pipeline has 42 drugs in development by companies and four by universities/ institutes. Some of the companies in the Ureter Cancer pipeline products market are: Merck, Shenzhen Geno-Immune Medical Institute and Jiangsu Hengrui Medicine.

The key targets in the Ureter Cancer pipeline products market include Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274), Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1), and Cells Expressing Receptor Tyrosine Protein Kinase ERBB 2 (Metastatic Lymph Node Gene 19 Protein or Proto Oncogene Neu or Proto Oncogene C ErbB 2 or Tyrosine Kinase Type Cell Surface Receptor HER2 or p185erbB2 or HER2 or CD340 or ERBB2 or EC 2.7.10.1).

The key mechanisms of action in the Ureter Cancer pipeline product include Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) Antagonist with seven drugs in Phase III. The Ureter Cancer pipeline products include nine routes of administration with the top ROA being Intravenous and ten key molecule types in the Ureter Cancer pipeline products market including Monoclonal Antibody, and Small Molecule.

Ureter Cancer overview

Ureter cancer or ureteral cancer is cancer of the ureter. Symptoms and signs of urethral cancer include bleeding from the urethra or blood in the urine, discharge from the urethra, and enlarged lymph nodes in the groin area. Risk factors include smoking. Treatment includes surgery, chemotherapy, and radiation therapy.

For a complete picture of Ureter Cancer’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.